Ongentys — Medical Mutual

Parkinson’s disease with hypomobility or 'off' episodes

Initial criteria

Patient experiences hypomobility or 'off' episodes; AND
Patient is receiving Ongentys in combination with levodopa/carbidopa; AND
Patient age ≥ 18 years; AND
Patient is not concurrently taking a non-selective monoamine oxidase inhibitor (MAOI) (such as: phenelzine, isocarboxazid, etc.); AND
Patient does not have pheochromocytoma, paraganglioma, or catecholamine secreting neoplasms; AND
Patient meets ONE of the following criteria (a or b): a) Patient has tried an entacapone product and had significant intolerance OR inadequate efficacy according to the prescriber; OR b) Patient is currently receiving Ongentys; AND
Ongentys is prescribed by, or in consultation with, a neurologist or prescriber specializing in the treatment of Parkinson’s disease

Patient age ≥ 18 years; AND
Patient is diagnosed with episodes of hypomobility ('off' episodes) associated with Parkinson’s disease; AND
Patient has experienced a positive clinical response to therapy; AND
Ongentys is prescribed by, or in consultation with, a neurologist or prescriber specializing in the treatment of Parkinson’s disease

1 year